Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery

Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery

Thumbnail Image
Download
Name

nihms973858.pdf

Size

1.28 MB

Format

Adobe PDF

Checksum (MD5)

535ae9e6c59e2d95f0451fdd82125683

Download all files submitted through automated deposit
sword-2019-01-18.original.zip (1.06 MB)
Author(s)
Tang, Li
•
Zheng, Yiran
•
Melo, Mariane Bandeira
•
Mabardi, Llian
•
Castaño, Ana P
•
Xie, Yu-Qing
•
Li, Na
•
Kudchodkar, Sagar B
•
Wong, Hing C
•
Jeng, Emily K
more
Date Issued
July 2018
Journal
Nature Biotechnology
Publisher
Nature Publishing Group
Citation
Tang, Li et al. “Enhancing T Cell Therapy through TCR-Signaling-Responsive Nanoparticle Drug Delivery.” Nature Biotechnology 36 (July 2018): 707-716. © 2018 Nature America, Inc., part of Springer Nature
Version
Author's final manuscript
Abstract
Adoptive cell therapy (ACT) with antigen-specific T cells has shown remarkable clinical success; however, approaches to safely and effectively augment T cell function, especially in solid tumors, remain of great interest. Here we describe a strategy to ‘backpack’ large quantities of supporting protein drugs on T cells by using protein nanogels (NGs) that selectively release these cargos in response to T cell receptor activation. We designed cell surface–conjugated NGs that responded to an increase in T cell surface reduction potential after antigen recognition and limited drug release to sites of antigen encounter, such as the tumor microenvironment. By using NGs that carried an interleukin-15 super-agonist complex, we demonstrated that, relative to systemic administration of free cytokines, NG delivery selectively expanded T cells 16-fold in tumors and allowed at least eightfold higher doses of cytokine to be administered without toxicity. The improved therapeutic window enabled substantially increased tumor clearance by mouse T cell and human chimeric antigen receptor (CAR)-T cell therapy in vivo.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Materials Science and Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
http://hdl.handle.net/1721.1/120102
DOI of Published Version
https://doi.org/10.1038/nbt.4181
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.